ArticleBMC public health2026
Factors influencing the survival of patients with advanced HIV disease in Guinea from 2015 to 2024.
Article in BMC public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAdvanced HIV disease (AHD) remains associated with substantial mortality in routine care settings. We aimed to describe survival patterns and identify predictors of mortality among patients with AHD managed in Guinea, while also examining programmatic pathway variables relevant to continuity of care, including transfer into one of the nine specialized AHD sites, return after previous loss to follow-up, and visit intensity during follow-up.
methodsWe conducted a retrospective cohort study using routine program data from patients with AHD enrolled in nine AHD care sites in Guinea between January 2015 and December 2024. Cohort entry was defined as the first documented AHD care visit at one of the nine study sites after AHD criteria were met. Follow-up was defined at the individual level from AHD cohort entry to death or censoring and was summarized in months and person-years. Median documented follow-up among analyzable individual follow-up intervals was summarized as median and interquartile range. Kaplan-Meier methods were used to describe survival patterns, and log-rank tests were used to compare curves. A principal multivariable Cox model was specified a priori using baseline predictors measured at cohort entry, and a secondary extended model additionally examined care-process variables accrued during follow-up. Programmatic pathway variables describing transfer into one of the nine study sites and return after previous loss to follow-up were examined descriptively and in exploratory analyses but were excluded from the principal prognostic model.
resultsAmong 24,090 individuals diagnosed with HIV during 2015-2024, 10,645 met the AHD definition and 1,289 died. Median documented follow-up was 2 months (IQR 1-5), corresponding to 2,529.8 person-years; the overall mortality incidence was 50.95 deaths per 100 person-years. In the principal multivariable model, mortality was higher among men (aHR 1.18, 95% CI 1.06-1.33), patients aged > 40 years (aHR 1.56, 95% CI 1.29-1.88), and those with WHO stage 3 (aHR 2.18, 95% CI 1.68-2.83) or stage 4 disease (aHR 4.20, 95% CI 3.19-5.52). Compared with new patients, transferred patients by ART initiation method had lower mortality (aHR 0.55, 95% CI 0.44-0.69). In the secondary extended model, confirmed TB or no documented TB screening at the last visit, fewer visits, and hospitalization during follow-up were associated with mortality in secondary exploratory care-process analyses. Exploratory pathway analyses showed lower observed hazards among patients transferred into the nine study sites and among those who returned after prior loss to follow-up; these findings were interpreted as referral, survivor selection, and re-engagement phenomena rather than as protective effects.
conclusionMortality among patients with AHD in Guinea remained high and was concentrated in the earliest documented period after cohort entry. Male sex, older age, and advanced WHO stage were the most consistent baseline predictors of death. The analyses also highlight the operational importance of continuity-of-care markers such as visit intensity, inter-site transfer, and return after interruption of follow-up, all of which can signal episodes during which adherence may be compromised in patients already presenting with advanced disease. These findings support earlier diagnosis, stronger implementation of the AHD package of care, improved TB screening and management, closer early follow-up, and stronger coordination of transfer and re-engagement pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.